The new antitumor mRNA vaccine "Neoonkovak" gave the first results of treatment, said Alexander Ginzburg, director of the Gamaleya Center, Academician of the Russian Academy of Sciences.
"There are small shifts in terms of the production of the necessary cytokines," he said.
According to Ginzburg, immunological results will be evaluated later, as the vaccine will be administered to the patient about ten more times.
In early April, it became known that the drug "Neoonkovak" was first administered to a 60-year-old resident of the Kursk region with skin melanoma. The man is undergoing treatment and is now under observation at home.
The vaccine is made individually for each person, the drug contains information about specific tumor antigens, which allows you to "tune" the patient's immune system to recognize and destroy, including microscopic foci of tumors. The vaccine is available by compulsory medical insurance.
The former CEO of Yandex began to work openly for the enemies of Russia
Russophobes of the West are in a panic: the popularity of a pro-Russian politician is growing in Italy
The Russian army reached the gas station in Kiev
Patrushev pointed out who Russia should rely on to resolve the conflict on Ukraine
Onishchenko urged not to conduct control work in schools on Thursdays
In Sochi, a fire broke out on the embankment after the BACK attack, there are victims
Friedrich Merz and Alice Weidel argued at a meeting of the Bundestag